Chimeric virus of porcine reproductive and respiratory syndrome virus and vaccine using the same
The low pathogenic pig reproductive and respiratory syndrome virus chimeric virus LMY+BP2017 was prepared by combining the nucleic acid sequence of a specific virus strain, which solved the problems of poor cross-protection ability and high pathogenicity of existing vaccines, and achieved different types of Effective protection and safety of viruses are improved.
Patent Information
- Application Number
- CN201980093073.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-11-13
- Filing Date
- 2019-12-09
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2039-12-09
AI Technical Summary
The existing pig reproductive and respiratory syndrome virus (PRRSV) vaccines have problems such as poor cross-protection ability, high pathogenicity and long development cycle, making it difficult to effectively prevent diseases caused by different types of virus strains.
A low pathogenic and high safety pig breeding and respiratory syndrome virus chimeric virus was developed by binding to the nucleic acid sequence of the ORF1a and ORF1b regions of the LMY ver2 mutant strain and the ORF2 to ORF7 regions of the BP2017-2 mutant strain The nucleic acid sequence was used to prepare the attenuated chimeric virus LMY+BP2017, which enhanced the secretion of neutralizing antibodies and significantly improved the immunity of pigs.
The chimeric virus significantly enhances the immunity of pigs, can effectively prevent and treat pig breeding and respiratory syndrome, improves the protection ability of different types of virus strains, shortens the vaccine development cycle, and improves safety.
Smart Images

Figure CN113544140B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a chimeric virus of porcine reproductive and respiratory syndrome virus (PRRSV) that can be used as a vaccine, and the chimeric virus of the present invention has low pathogenicity and high safety compared with its parent strain. The PRRSV chimeric virus of the present invention can enhance the secretion of neutralizing antibodies associated with cross immunity and provide a vaccine that can effectively protect porcine reproductive and respiratory syndrome. Background Art
[0002] Porcine reproductive and respiratory syndrome (PRRS) is the most harmful infectious disease to the domestic pig industry, along with porcine circovirus infection and foot-and-mouth disease. PRRS causes reproductive disorders such as infertility, miscarriage, premature birth or stillbirth in pregnant sows, and causes respiratory symptoms such as sneezing and fever in piglets and fattening pigs. Generally speaking, severe respiratory symptoms are caused by secondary infections such as bacteria after viral infection, but in the case of chronic infection, weight gain is reduced and mortality is increased without characteristic clinical symptoms.
[0003] This viral disease was first discovered in the United States in 1987, then in Europe, and in Asia in the early 1990s. To date, PRRS has been endemic in pig-raising countries and has spread around the world, causing huge economic losses every year.
[0004] The pathogen that causes PRRS is a PRRS virus belonging to the order Nidovirales, family Arteriviridae, genus Arteriviru. The PRRS virus has a positive-sense single-stranded RNA genome of approximately 15.4 kilobases in size. The genome of the PRRS virus has 9 ORFs (Conzelmann et al., 1993; Meulenberg et al., 1993). Among them, ORF1a and ORF1b encoding nonstructural proteins (NSP) account for approximately 80% of the viral genome (Bautista et al., 2002; Meulenberg et al., 1993; Snijder and Meulenberg, 1998, 2001). Among the nonstructural proteins, NSP1-α, NSP-1β, and NSP2 to NSP8 are known to be located in ORF1a, and NSP9 to NSP12 are known to be located in ORF1b. Glycosylated structural proteins GP2, GP3, GP4 and GP5 as well as non-glycosylated membrane (M) protein and nucleocapsid (N) protein are encoded by ORF2-7, accounting for the remaining 20%. Minor structural proteins GP2, GP3 and GP4 form heterotrimers and play a role in the virus invading host cells, and major structural proteins GP5 and M form heterodimers and are used to increase the infectivity of the virus.
[0005] Due to the nature of RNA viruses, PRRS viruses are highly mutated, so there are many differences between viruses. PRRS viruses are mainly divided into North American and European types. There is type I (Lelystad virus, LV) representing the European type, and type II representing the North American strain (North American strain) ATCC VR2332 (the genome sequence of VR2332 is shown in GenBank accession number AY150564) (Murtaugh et al., Arch Virol. 1995; 140: 1451-1460).
[0006] It is known that there is a genetic difference of up to 40% between the North American type and the European type, so they cannot cross-protect each other. In addition, even between mutants belonging to the same type, cross-protection is not often performed (Meng, XJ et al., 2000). For this reason, vaccines based on standard mutants have been produced for each standard mutant, but due to poor cross-protection ability, PRRS cannot be effectively prevented. In order to overcome this problem, various attempts have been made to produce vaccines with effective safety, immunogenicity and protection ability.
[0007] Due to the severity of this disease, since the discovery of the porcine reproductive and respiratory syndrome virus (PRRSV) that causes porcine reproductive and respiratory syndrome (PRRS), a large amount of effort has been invested in developing a preventive method for this virus for about 20 years, but no prevention and management methods have been developed. Various vaccines such as inactivated vaccines and attenuated live vaccines have been developed to control porcine reproductive and respiratory syndrome (PRRS), but it has been found that only attenuated vaccines with susceptible infectivity can induce satisfactory protective effects. However, due to the existence of many kinds of porcine reproductive and respiratory syndrome viruses (PRRSV), there is no cross immunity between various viruses, so it is difficult to prevent various porcine reproductive and respiratory syndrome viruses (PRRSV) with a vaccine. In addition, current attenuated vaccines can only be produced by continuous passage in cell lines of other animal species for more than 100 to 200 generations, so there is a long development cycle, and it is difficult to ensure the problem of effectiveness and safety. For this reason, vaccines based on standard mutants have been produced for each standard mutant, but due to poor cross protection ability, PRRS can not be effectively prevented.
[0008] In order to overcome the above problems, various attempts have been made to produce vaccines with effective safety, immunogenicity and protection (Application No. 10-2011-7004020, Invention Name: Vaccine against Highly Pathogenic Porcine Reproductive and Respiratory Syndrome (HPPRRS)). Summary of the invention
[0009] Technical issues
[0010] The present invention relates to a chimeric virus of porcine reproductive and respiratory syndrome virus (PRRSV) with low pathogenicity and high safety and enhanced secretion of neutralizing antibodies, a vaccine containing the same and a preparation method thereof.
[0011] In one example, a chimeric virus may comprise:
[0012] (1) a nucleic acid sequence of ORF1a and ORF1b derived from the LMY ver2 mutant strain with a deposit number of KCTC 13394BP, or a nucleic acid sequence having a sequence homology of 70% or more to the nucleic acid sequence while maintaining functional equivalence to the nucleic acid sequence, and
[0013] (2) The nucleic acid sequence of the ORF2 to ORF7 region of the BP2017-2 isolate with the deposit number KCTC 13393BP, or a nucleic acid sequence having a sequence homology of 70% or more to the nucleic acid sequence while maintaining functional equivalence to the nucleic acid sequence.
[0014] Technical Solution
[0015] The present invention relates to a chimeric virus of porcine reproductive and respiratory syndrome virus (PRRSV) that can be used as a vaccine. The PRRSV chimeric virus of the present invention is attenuated, and therefore has low pathogenicity and high safety compared with its parent strain, and enhances the secretion of neutralizing antibodies associated with cross immunity, thereby significantly enhancing the immunity of pigs. Therefore, it can be used as an effective vaccine for preventing and treating PRRS disease.
[0016] Hereinafter, the present invention will be described in more detail.
[0017] As used herein, "attenuated virus" refers to a non-toxic virus that is capable of inducing an immune response in a target mammal without causing clinical symptoms of PRRS disease, and also refers to a reduction in clinical symptoms in animals infected with an attenuated virus and not receiving the attenuated virus, or a reduction in the severity of symptoms compared to a "control" animal infected with a non-attenuated PRRS virus. In this context, the term "reduction" or "reduced" refers to a reduction of at least 10%, preferably 25%, more preferably 50%, or most preferably 100% or more compared to a control as defined above.
[0018] As used herein, a "vaccine composition" can be a PRRS chimeric virus or any immunogenic fragment or portion thereof, preferably an attenuated PRRS chimeric virus, such as a PRRS chimeric virus of the present invention. This will result in an "immune response", such as a cell and / or antibody-mediated immune response to PRRSV. Preferably, the vaccine composition is capable of providing preventive immunity against PRRSV infection and its associated clinical symptoms.
[0019] As used herein, "immune response" means an immune response mediated by any cell and / or antibody directed to a chimeric virus or vaccine administered to an animal to which a PRRSV chimeric virus of the present invention or a vaccine composition comprising the same is administered. Generally, an "immune response" includes one or more of the following effects, but is not limited thereto: the production or activation of antigens contained in the corresponding composition or vaccine, or antibodies, B cells, helper T cells, suppressive T cells and / or cytotoxic T cells and / or γδT cells specifically induced to the antigen. Preferably, the host exhibits a therapeutic or prophylactic immune response compared to a control that has not received an immunogenic composition or vaccine, thereby improving resistance to new infections and / or reducing the clinical severity of the disease. Such prevention will be demonstrated at most by the absence of symptoms associated with the above-mentioned host infection and a reduction in the frequency or severity of the above-mentioned symptoms.
[0020] As used herein, "pigs" and "piglet" are used interchangeably.
[0021] "Vaccination" refers to the administration of a PRRSV chimeric virus as described herein or a vaccine comprising the same prior to exposure to PRRS disease.
[0022] "Prevent" or "prevention" refers to a reduction in the severity or frequency of clinical occurrence or symptoms of PRRS as a result of administering the PRRSV virus of the present invention or a vaccine composition comprising the same. The reduction in severity or frequency is the result compared to an animal or animal group that has not been administered the PRRSV chimeric virus of the present invention or a vaccine composition comprising the same. The animal may preferably be a pig.
[0023] For convenience, the sequences herein are described in terms of DNA nucleotides. When the polynucleotide type is RNA, it refers to a sequence in which all or part of the thymine (T) in the nucleotide sequence is replaced by uracil (U).
[0024] Here, "consisting of" a specific nucleotide sequence and / or amino acid sequence includes all of: comprising the sequence, substantially comprising the sequence and / or consisting of the sequence, and can be appropriately replaced and used if necessary.
[0025] The present invention provides an attenuated chimeric virus against porcine reproductive and respiratory syndrome virus (PRRSV), a viral disease that infects pigs.
[0026] To achieve the above object, the present invention provides a polynucleotide comprising a structure of structural formula 1:
[0027] [Structural Formula 1]
[0028] 5'-[X]-[Y]-3'
[0029] In the formula, [X] is the nucleic acid sequence of the genes in the ORF1a and ORF1b regions of the LMY ver2 mutant strain with a deposit number of KCTC 13394BP, or a nucleic acid sequence having 70% or higher sequence homology with the nucleic acid sequence of the genes in the ORF1a and ORF1b regions, which includes the nucleic acid sequence of the NSP1 gene (NSP1-α gene and NSP1-β gene) of the LMY ver2 mutant strain with a deposit number of KCTC 13394BP, or a nucleic acid sequence having 70% or higher sequence homology with the nucleic acid sequence within the scope of maintaining equivalent functions, for example, including the nucleic acid sequence of the NSP1 gene of the LMY ver2 mutant strain, or a nucleic acid sequence having 70% or higher sequence homology with the nucleic acid sequence within the scope of maintaining equivalent functions; [Y] is the nucleic acid sequence of the genes in the ORF2 to ORF7 regions of the BP2017-2 mutant strain with a deposit number of KCTC13393BP, or a nucleic acid sequence having 70% or higher sequence homology with the nucleic acid sequence within the scope of maintaining equivalent functions. As used herein, "equivalent function" may refer to a function that is qualitatively (activity) and / or quantitatively (level) identical or similar to the desired function. For example, the amino acid sequence of the protein encoded by the gene may be identical to the amino acid sequence of the protein encoded by the wild-type gene.
[0030] In one example, [X] may include all types of point mutations (silent mutations) occurring in the nucleic acid sequence of the NSP1 gene consisting of the nucleotide sequence of SEQ ID NO: 11 within the range of maintaining the amino acid sequence of the NSP1 protein encoded by the NSP1 gene, for example, and can be freely selected and used within the range of aiming to reduce the CBP value of the NSP1 gene.
[0031] For example, [X] may include the following mutation: in the nucleic acid sequence of the NSP1 gene consisting of the nucleotide sequence of SEQ ID NO: 11, one or more, 25 or more, 66 or more, 80 or more, or all 91 bases selected from the group consisting of the following positions are substituted: position 222, position 225, position 237, position 240, position 252, position 306, position 309, position 312, position 315, position 324, position 327, position 330, position 333, Position 336, position 339, position 342, position 345, position 357, position 363, position 366, position 378, position 379, position 381, position 393, position 396, position 543, position 546, position 549, position 555, position 558, position 561, position 573, position 579, position 582, position 588, position 612, position 618, position 621, position 627, position 630 33. Position 639, Position 654, Position 673, Position 675, Position 678, Position 681, Position 684, Position 705, Position 708, Position 729, Position 735, Position 738, Position 741, Position 744, Position 747, Position 771, Position 786, Position 789, Position 792, Position 810, Position 825, Position 828, Position 838, Position 840, Position 846, Position 849, Position 858, position 867, position 879, position 882, position 885, position 891, position 900, position 903, position 906, position 924, position 936, position 939, position 948, position 954, position 963, position 966, position 1026, position 1029, position 1038, position 1047, position 1053, position 1066, position 1068, position 1086 and position 1110.
[0032] In one example, [X] may include one or more, 25 or more, 66 or more, 80 or more, or all 91 mutations selected from the group consisting of the following mutations in the nucleic acid sequence of the NSP1 gene consisting of the nucleotide sequence of SEQ ID NO: 11: a mutation in which G at position 222 is substituted with C, a mutation in which C at position 225 is substituted with A, a mutation in which T at position 327 is substituted with C, a mutation in which A at position 240 is substituted with T, a mutation in which T at position 252 is substituted with C, a mutation in which A at position 306 is substituted with C, a mutation in which T at position 309 is substituted with C, a mutation in which G at position 312 is substituted with A, a mutation in which C at position 315 is substituted with A, a mutation in which T at position 324 is substituted with C, mutation, mutation of C at position 327 replaced by G, mutation of G at position 330 replaced by A, mutation of C at position 333 replaced by T, mutation of C at position 336 replaced by G, mutation of T at position 339 replaced by C, mutation of A at position 342 replaced by T, mutation of T at position 345 replaced by A, mutation of A at position 357 replaced by G, mutation of T at position 363 replaced by A, mutation of T at position 366 replaced by C, mutation of C at position 378 replaced by T, mutation of C at position 379 replaced by A, mutation of C at position 381 replaced by G, mutation of T at position 393 replaced by C, mutation of T at position 39 6 was replaced by A, 543 by T, 546 by T, 549 by C, 555 by T, 558 by T, 561 by T, 573 by C, 579 by T, 582 by G, 588 by T, 612 by T, 618 by G, 621 by T, 627 by A, 630 by C, 641 by C, 647 by C, 650 by C, 661 by C, 677 by C, 681 by C, 690 by C, 728 by C, 734 by C, 729 by C, 743 by C, 754 by C, 768 by C, 770 by C, 785 by C, 791 by C, 807 by C, 813 by C, 821 by C, 827 by C, 830 by C, 847 by C, 850 by C, 861 by C, 871 by C, 880 by C, 891 by C, 908 by C, 914 by C, 923 by C, 924 by C, 932 by C, 945 by C, 950 by C, 961 by C, 970 by C, 981 by C, 990 by C, 991 by C, 992 by C, 993 by C, 994 by C, 995 by C, 996 by C, 997 by C, 998 by C mutation at position 633 is replaced by C, mutation at position 639 is replaced by G, mutation at position 654 is replaced by T, mutation at position 673 is replaced by T, mutation at position 675 is replaced by A, mutation at position 678 is replaced by T, mutation at position 681 is replaced by G, mutation at position 684 is replaced by G, mutation at position 705 is replaced by C, mutation at position 708 is replaced by T, mutation at position 729 is replaced by C, mutation at position 735 is replaced by C, mutation at position 738 is replaced by T, mutation at position 741 is replaced by T,The mutations at position 744 were replaced by T to C, the mutations at position 747 were replaced by T to A, the mutations at position 771 were replaced by T to C, the mutations at position 786 were replaced by T to C, the mutations at position 789 were replaced by C to T, the mutations at position 792 were replaced by T to G, the mutations at position 810 were replaced by C to T, the mutations at position 825 were replaced by T to C, the mutations at position 828 were replaced by C to T, the mutations at position 838 were replaced by T to G, the mutations at position 839 were replaced by T to G, the mutations at position 840 were replaced by T to G, the mutations at position 841 were replaced by T to G, the mutations at position 843 were replaced by T to G, the mutations at position 844 were replaced by T to C, the mutations at position 845 were replaced by T to G, the mutations at position 846 were replaced by T to G, the mutations at position 847 were replaced by T to G, the mutations at position 848 were replaced by T to G, the mutations at position 849 were replaced by T to G, the mutations at position 850 were replaced by T to G, the mutations at position 851 were replaced by T to G, the mutations at position 852 were replaced by T to G, the mutations at position 853 were replaced by T to G, the mutations at position 854 were replaced by T to G, the mutations at position 855 were replaced by T to G, the mutations at position 856 were replaced by T to G, the mutations at position 857 were replaced by T to G, the mutations at position 858 were replaced by T to G, the mutations at position The mutations at position 840 were replaced by G to C, the mutation at position 846 was replaced by C to G, the mutation at position 849 was replaced by G to A, the mutation at position 858 was replaced by A to G, the mutation at position 867 was replaced by T to C, the mutation at position 879 was replaced by T to C, the mutation at position 882 was replaced by C to G, the mutation at position 885 was replaced by C to T, the mutation at position 891 was replaced by C to T, the mutation at position 90 The mutations were as follows: T at position 900 was substituted with C, C at position 903 was substituted with A, T at position 906 was substituted with C, G at position 924 was substituted with T, T at position 936 was substituted with C, T at position 939 was substituted with C, A at position 948 was substituted with C, A at position 954 was substituted with C, A at position 963 was substituted with T, T at position 966 was substituted with C, and G at position 924 was substituted with T. mutation, A at position 1026 is substituted with G, G at position 1029 is substituted with C, C at position 1038 is substituted with T, T at position 1047 is substituted with C, T at position 1053 is substituted with C, A at position 1066 is substituted with C, A at position 1068 is substituted with C, C at position 1086 is substituted with T, and T at position 1110 is substituted with C.
[0033] For example, [X] can be the nucleic acid sequence of the NSP1 gene (SEQ ID NO: 12) and / or NSP1-β (SEQ ID NO: 1; base position 609 at the 5' end of SEQ ID NO: 12) of the LMY ver2 mutant strain with a deposit number of KCTC 13394BP, or a nucleic acid sequence having a sequence homology of 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, or 99.5% or more to the nucleic acid sequence while maintaining equivalent functions.
[0034] For example, [Y] can be the gene nucleic acid sequence of the ORF2 to ORF7 region of the BP2017-2 mutant strain with a deposit number of KCTC 13393BP, or a nucleic acid sequence having a sequence homology of 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, or 99.5% or more to the nucleic acid sequence while maintaining equivalent functions.
[0035] According to an example of the present invention, [A]n may be further included at the 3' end of [Y] in Structural Formula 1. n is the number of nucleotides containing base A, and may be an integer from 10 to 100. Preferably, n may be an integer from 10 to 80, 10 to 70, 10 to 60, 10 to 50, 10 to 40, 10 to 30, 15 to 80, 15 to 70, 15 to 60, 15 to 50, 15 to 40, 15 to 30, 20 to 30, or 20 to 26.
[0036] The polynucleotide may be RNA, reverse transcriptase of RNA (DNA) or a combination thereof. The polynucleotide may function as the genome of a PRRSV chimeric virus.
[0037] Accordingly, another example of the present invention provides a chimeric virus of porcine reproductive and respiratory syndrome virus (PRRSV) comprising a polynucleotide having the structure of Structural Formula 1. The genome of the PRRSV chimeric virus can be DNA or RNA, preferably RNA.
[0038] [X] corresponds to the NSP1 gene region of NSP1-β of the LMY ver2 mutant strain deposited with KCTC 13394BP, and can be a gene fragment obtained by treating the genome of the LMY ver2 mutant strain with restriction enzymes AscI and PacI. For example, [X] can contain the nucleic acid sequence of SEQ ID NO:1 and / or SEQ ID NO:12 or a nucleic acid sequence having a sequence homology of 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, or 99.5% or more to the nucleic acid sequence within the range of maintaining equivalent functions.
[0039] [Y] corresponds to the ORF2 to ORF7 region of the BP2017-2 mutant strain with a deposit number of KCTC 13393BP, and can be a gene fragment obtained by treating the genome of the BP2017-2 mutant strain with restriction enzymes AscI and PacI. For example, [Y] can contain the nucleic acid sequence of SEQ ID NO:2 or a nucleic acid sequence having a sequence homology of 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, or 99.5% or more to the nucleic acid sequence while maintaining equivalent functions.
[0040] In one example, Structural Formula 1 may include the nucleic acid sequence of SEQ ID NO: 4 or a nucleic acid sequence having a sequence homology of 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, or 99.5% or more to the nucleic acid sequence within the scope of maintaining equivalent functions. For example, Structural Formula 1 may be the nucleic acid sequence of SEQ ID NO: 4.
[0041] In Table 1 below, the portion marked in bold in the nucleotide sequence of the NSP1 gene of LMY ver2 represents the NSP1-β region.
[0042] [Table 1]
[0043]
[0044]
[0045]
[0046]
[0047] [Table 2]
[0048]
[0049]
[0050]
[0051]
[0052]
[0053]
[0054]
[0055]
[0056]
[0057]
[0058] (In the table, the polynucleotide (RNA) provided herein may include a nucleic acid sequence in which T is replaced by U in the sequence shown in SEQ ID No: 1 to 4.)
[0059] The present invention provides a PRRSV chimeric virus comprising a polynucleotide of structural formula 1 as a genome. The PRRSV chimeric virus may include progeny viruses cultured for 1 to 80 generations, 1 to 70 generations, 1 to 60 generations, 1 to 50 generations, 1 to 40 generations, 1 to 30 generations, 1 to 20 generations, or 1 to 10 generations.
[0060] [Structural Formula 1]
[0061] 5'-[X]-[Y]-3'
[0062] In the formula, [X] is the nucleic acid sequence of the NSP1 gene and / or NSP1-β of the LMY ver2 mutant strain with a deposit number of KCTC 13394BP, or a nucleic acid sequence having a sequence homology of 70% or higher to the nucleic acid sequence, and [Y] is the gene nucleic acid sequence of the ORF2 to ORF7 region of the BP2017-2 mutant strain with a deposit number of KCTC 13393BP, or a nucleic acid sequence having a sequence homology of 70% or higher to the nucleic acid sequence.
[0063] For example, [X] can be the nucleic acid sequence of the NSP1 gene and / or NSP1-β of the LMY ver2 mutant strain with a deposit number of KCTC 13394BP, or a nucleic acid sequence having a sequence homology of 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, or 99.5% or more to the nucleic acid sequence.
[0064] In addition, [Y] can be the gene nucleic acid sequence of the ORF2 to ORF7 region of the BP2017-2 mutant strain with a deposit number of KCTC 13393BP, or a nucleic acid sequence having a sequence homology of 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, or 99.5% or more to the nucleic acid sequence.
[0065] According to an example of the present invention, [A]n may be further included at the 3' end of [Y] in Structural Formula 1. n is the number of nucleotides containing base A, and may be an integer from 10 to 100, for example, an integer from 10 to 80, 10 to 70, 10 to 60, 10 to 50, 10 to 40, 10 to 30, 15 to 80, 15 to 70, 15 to 60, 15 to 50, 15 to 40, 15 to 30, 20 to 30, or 20 to 26.
[0066] The polynucleotide may be RNA, a reverse transcriptase (DNA) of RNA, or a combination thereof. The polynucleotide may function as a genome of a PRRSV chimeric virus. Accordingly, another example of the present invention provides a chimeric virus of porcine reproductive and respiratory syndrome virus (PRRSV) comprising a polynucleotide having a structure of formula 1. The genome of the PRRSV chimeric virus may be DNA or RNA, preferably RNA.
[0067] [X] corresponds to the NSP1 gene region of NSP1-β of the LMY ver2 mutant strain deposited with KCTC 13394BP, and may be a gene fragment obtained by treating the genome of the LMY ver2 mutant strain with restriction enzymes AscI and PacI. For example, [X] may comprise the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence having a sequence homology of 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, or 99.5% or more to the nucleic acid sequence within the range of maintaining equivalent functions.
[0068] [Y] corresponds to the ORF2 to ORF7 region of the BP2017-2 mutant strain with a deposit number of KCTC 13393BP, and can be a gene fragment obtained by treating the genome of the BP2017-2 mutant strain with restriction enzymes AscI and PacI. For example, [Y] may contain the nucleic acid sequence of SEQ ID NO:2 or a nucleic acid sequence having a sequence homology of 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, or 99.5% or more to the nucleic acid sequence while maintaining equivalent functions.
[0069] In one example, Structural Formula 1 may include the nucleic acid sequence of SEQ ID NO: 4 or a nucleic acid sequence having a sequence homology of 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, or 99.5% or more to the nucleic acid sequence within the scope of maintaining equivalent functions. For example, Structural Formula 1 may be the nucleic acid sequence of SEQ ID NO: 4.
[0070] A specific example provides a PRRSV chimeric virus, which comprises a polynucleotide containing SEQ ID NO: 4 as a genomic nucleic acid sequence, and the PRRSV chimeric virus is named LMY+BP2017. The LMY+BP2017 virus may be a virus with a deposit number of KCTC 13394BP.
[0071] The LMY ver2 mutant strain as the LMY+BP2017 chimeric virus framework can be a PRRSV mutant strain containing a mutant NSP1-β, in which at least one base in the non-structural protein 1 (NSP1) of SEQ ID NO: 5 of the LMY parent strain (GenBank Accession No. DQ473474.1.) is replaced.
[0072] The nucleotide sequence to be replaced in the nucleotide sequence of the gene encoding NSP1 and / or NSP1-β of the MLY strain can be selected using a known synthetic attenuated virus engineering (SAVE) program, preferably, can be selected using the SAVE program developed by the present inventors. In particular, the nucleotide sequence to be replaced can be a nucleotide sequence that is optimized by analyzing the genetically highly safe NSP1 region in the genome of the parent strain LMY using the SAVE program developed by the present inventors, and selecting and replacing part or all of the nucleotide sequence showing a higher codon pair bias (CPB). The deoptimized nucleotide sequence may be included in the sequence represented by SEQ ID One or more, 25 or more, 66 or more, 80 or more, or all 91 mutations are selected from the group consisting of the following in the gene encoding the NSP1 protein of the LMY strain composed of the nucleotide sequence of NO:11: a mutation in which G at position 222 is replaced by C, a mutation in which C at position 225 is replaced by A, a mutation in which T at position 327 is replaced by C, a mutation in which A at position 240 is replaced by T, a mutation in which T at position 252 is replaced by C, a mutation in which A at position 306 is replaced by C , mutation of T replaced by C at position 309, mutation of G replaced by A at position 312, mutation of C replaced by A at position 315, mutation of T replaced by C at position 324, mutation of C replaced by G at position 327, mutation of G replaced by A at position 330, mutation of C replaced by T at position 333, mutation of C replaced by G at position 336, mutation of T replaced by C at position 339, mutation of A replaced by T at position 342, mutation of T replaced by The mutations at position 357 are replaced by A, the mutation at position 357 is replaced by G, the mutation at position 363 is replaced by A, the mutation at position 366 is replaced by C, the mutation at position 378 is replaced by T, the mutation at position 379 is replaced by A, the mutation at position 381 is replaced by G, the mutation at position 393 is replaced by C, the mutation at position 396 is replaced by A, the mutation at position 543 is replaced by C, the mutation at position 546 is replaced by C, the mutation at position 549 is replaced by The mutations are: C at position 554 is substituted with A, T at position 555 is substituted with C, T at position 558 is substituted with C, T at position 561 is substituted with A, C at position 573 is substituted with T, T at position 579 is substituted with C, G at position 582 is substituted with T, T at position 588 is substituted with C, T at position 612 is substituted with C, G at position 618 is substituted with C, T at position 621 is substituted with C,Mutation of A replaced by T at position 627, mutation of T replaced by C at position 633, mutation of T replaced by G at position 639, mutation of C replaced by T at position 654, mutation of C replaced by T at position 673, mutation of C replaced by A at position 675, mutation of C replaced by T at position 678, mutation of C replaced by G at position 681, mutation of C replaced by G at position 684, mutation of G replaced by C at position 705, mutation of C replaced by T at position 708, mutation of A replaced by C at position 729, mutation of T replaced by C at position 735, mutation of G replaced by C at position 738 Mutation substituted with T, mutation substituted with C at position 741, mutation substituted with C at position 744, mutation substituted with A at position 747, mutation substituted with C at position 771, mutation substituted with C at position 786, mutation substituted with C at position 789, mutation substituted with T at position 792, mutation substituted with T at position 810, mutation substituted with C at position 825, mutation substituted with T at position 828, mutation substituted with C at position 838, mutation substituted with C at position 840, mutation substituted with C at position 846 , mutation of G at position 849 replaced by A, mutation of A at position 858 replaced by G, mutation of T at position 867 replaced by C, mutation of T at position 879 replaced by C, mutation of C at position 882 replaced by G, mutation of C at position 885 replaced by T, mutation of C at position 891 replaced by T, mutation of T at position 900 replaced by C, mutation of C at position 903 replaced by A, mutation of T at position 906 replaced by C, mutation of G at position 924 replaced by T, mutation of T at position 936 replaced by C, mutation of T at position 939 replaced by C, mutation of T at position 948 replaced by G, mutation of T at position 949 replaced by G, mutation of T at position 950 replaced by G, mutation of T at position 951 replaced by G, mutation of T at position 952 replaced by G, mutation of T at position 953 replaced by G, mutation of T at position 954 replaced by G, mutation of T at position 955 replaced by G, mutation of T at position 956 replaced by G, mutation of T at position 957 replaced by G, mutation of T at position 958 replaced by G A is substituted with C, A at position 954 is substituted with C, A at position 963 is substituted with T, T at position 966 is substituted with C, A at position 1026 is substituted with G, G at position 1029 is substituted with C, C at position 1038 is substituted with T, T at position 1047 is substituted with C, T at position 1053 is substituted with C, A at position 1066 is substituted with C, A at position 1068 is substituted with C, C at position 1086 is substituted with T, and T at position 1110 is substituted with C, but are not limited thereto.
[0073] Using the SAVE program, a computer algorithm can be used to quantify the CPB, which is the deviation generated by the interaction when the viral gene codons are arranged in pairs, and because when the CPB value is reduced, the proliferation characteristics of the virus will also be reduced (deoptimized) and attenuated (Virus Attenuation by Genome-Scale Changes in Codon Pair Bias, Science, 2008, J. Robert Coleman et al.), the LMY ver2 attenuated mutant strain for preparing the chimeric virus of the present invention can be generated by replacing part of the nucleotide sequence with a high CPB value with a nucleotide sequence with a low CPB value, or preferably performing silent mutation according to the principle of codon pair deoptimization. The LMYver2 mutant strain may include a gene encoding the NSP1-β protein composed of the nucleotide sequence of SEQ ID NO: 6 or a gene encoding the NSP1 protein composed of the nucleotide sequence of SEQ ID NO: 12.
[0074] In addition, the present invention can provide a cell containing the genome of the PRRSV chimeric virus of the present invention. The cell refers to a cell into which the genome (DNA, RNA or a vector containing them) of the chimeric virus or a chimeric virus containing the genome is transfected to produce a large amount of the chimeric virus, and the type of the cell is not particularly limited as long as it is within the scope of the purpose.
[0075] According to one example of the present invention, a porcine reproductive and respiratory syndrome virus vaccine composition may be provided, the vaccine composition comprising a PRRSV chimeric virus or its subcultured progeny.
[0076] The progeny of the subculture may include progeny viruses of passages 1 to 80, 1 to 70, 1 to 60, 1 to 50, 1 to 40, 1 to 30, 1 to 20, or 1 to 10.
[0077] According to an example of the present invention, the vaccine can be a live vaccine or a dead vaccine, but is preferably a live vaccine. Specifically, the attenuated PRRS chimeric virus described herein can be a modified live vaccine containing one or more of the above-mentioned virus strains in a living state in a pharmaceutically acceptable carrier. In addition, or alternatively, inactivated viruses can be used to prepare dead vaccines.
[0078] The vaccine may also contain one or more selected from the group consisting of a carrier, a diluent, an excipient and an adjuvant. The type of pharmaceutically acceptable carrier is not particularly limited, but may include any solvent, dispersion medium, coating, stabilizer, preservative, antibiotic and antifungal agent, isotonic agent, absorption delay agent, etc.
[0079] On the other hand, the effective dose of the attenuated chimeric virus of the present invention contained in the vaccine composition can be the amount of virus that causes or is capable of causing an immune response in an animal administered with the effective dose of the virus. The effective amount may depend on the vaccine components and the administration schedule. The dose of the vaccine composition can be in the range of TCID 50 is in the range of 2 to 6, preferably TCID 50 It is in the range of 3 to 4 and may vary according to the type of subject, but is not limited thereto.
[0080] The genome of the LMY-BP2017 chimeric virus of the present invention and the vaccine composition comprising the genome can be used to protect pigs from PRRS disease. In addition, subunits comprising immunogenic fragments or portions of the PRRS chimeric virus can be used to protect pigs from PRRS disease. The attenuated chimeric virus of the present invention or the vaccine composition comprising the attenuated chimeric virus can be administered prophylactically before the pig is exposed to the PRRS virus strain that causes PRRS, can be administered to the pig while the pig is exposed to the PRRS virus strain, and can be administered therapeutically after the target pig is exposed to the virus strain.
[0081] The vaccine composition provided by the present invention can be used to prevent porcine reproductive and respiratory syndrome virus (PRRS), for example, to prevent PRRS caused by North American PRRSV. In one example, the North American PRRSV can be a type II VR2332 virus strain.
[0082] The attenuated PRRSV chimeric virus of the present invention or a vaccine composition comprising the attenuated PRRSV chimeric virus can be administered orally, parenterally, subcutaneously, intramuscularly, intradermally, sublingually, transdermally, rectally, transmucosally, by inhalation, by topical or buccal administration, or a combination thereof. In addition, the attenuated PRRS chimeric virus can be administered in the form of an implant that allows sustained release of the attenuated virus.
[0083] The attenuated PRRSV chimeric virus of the present invention or the vaccine composition comprising the attenuated PRRSV chimeric virus can be administered by injection, inhalation or transplantation, and injection is particularly preferred. Depending on the time and effectiveness of the required vaccination or treatment, the attenuated PRRSV chimeric virus or the vaccine composition comprising the attenuated PRRSV chimeric virus can be administered intermittently once or multiple times a day at different doses, for example, for several days, weeks or months. The injection can be performed by injecting the required amount or by subcutaneous injection or by spraying into the nasal cavity, or by continuous infusion.
[0084] According to one example of the present invention, the PRRSV chimeric virus of the present invention can be TCID 50 The value is the TCID of the parent strain (GenBank accession number DQ473474.1.) 50The value is 0.01 times to 0.1 times of the virus, TCID 50 The value is the TCID of the virus measured by inoculating the chimeric virus and its parental strain into porcine lung macrophages 50 Preferably, the measurement time is 2 days later, TCID 50 The value may be 0.05 to 0.1 times. The TCID of the PRRSV chimeric virus of the present invention 50 values are lower than the parent strain and have reduced proliferation properties and are attenuated.
[0085] In addition, the present invention provides a virus, the neutralizing antibody content of the mutant of the virus is measured by inoculating pigs with the PRRSV chimeric virus of the present invention and its parent strain, which is 2 to 8 times that of the parent strain, preferably 2 to 4 times. The measurement time is preferably after 28 days. Neutralizing antibodies refer to antibodies that have neutralizing ability against VR2332, which is a representative North American PRRSV strain. Therefore, when the attenuated chimeric virus of the present invention or a vaccine composition comprising the attenuated chimeric virus is inoculated into pigs, the titer of the neutralizing antibodies of the pigs increases, and the expression of the immune factors of the pigs increases, so the immune effect against PRRS can be significantly increased.
[0086] According to a specific example, the CPB value of the PRRSV chimeric virus LMY+BP2017 of the present invention shows a value lower than that of the LMY parent strain (GenBank accession number DQ473474.1.), preferably -0.39 to 0, more preferably -0.35 to -0.20, appropriately -0.35 to -0.26, for example -0.2393184052058128. When the CPB value is less than -0.39, it is difficult to produce the virus, and when the CPB value exceeds 0, there is a problem that the virus can be produced but the proliferation characteristics are not reduced, and therefore the virus is not attenuated. Therefore, the attenuated LMY+BP2017 chimeric virus of the present invention preferably has the above-mentioned CPB value.
[0087] In addition, the present invention also provides a LMY+BP2017 chimeric virus having CpG and UpA values 1.0 to 3.0 times that of the parent strain (GenBank accession number DQ473474.1.). The change in the CpG and UpA ratios is an inevitable result of the deoptimization process. When the CpG and UpA values of eukaryotic genes increase, cell stress will be caused, thereby reducing the proliferation characteristics of the virus, thereby attenuating the virus. The LMY+BP2017 chimeric virus of the present invention has higher CpG and UpA values than the parent strain, preferably 1.0 to 3.0 times the CpG and UpA values of the parent strain. For example, the CpG of the attenuated chimeric virus of the present invention can be 1.1753, and UpA can be 1.03.
[0088] According to an example of the present invention, a method for producing a chimeric virus of porcine reproductive and respiratory syndrome virus comprises treating the genome of the LMY ver2 mutant strain with a deposit number of KCTC 13394BP with restriction enzymes AscI and PacI to prepare polynucleotide fragments, treating the genome of the BP2017-2 mutant strain with a deposit number of KCTC 13393BP with restriction enzymes AscI and PacI to prepare polynucleotide fragments, and recombining the polynucleotide fragments of LMY ver2 and the polynucleotide fragments of BP2017-2 to prepare infectious clones.
[0089] The polynucleotide fragment prepared by treating the genome of the LMY ver2 mutant strain with restriction enzymes AscI and PacI may include a region encoding NSP1-β.
[0090] The polynucleotide fragment prepared by treating the genome of the BP2017-2 mutant strain with restriction enzymes AscI and PacI may include ORF2 to ORF7 regions.
[0091] When the fragments are recombined, a ligase can be used, and chimeric viruses can be prepared by inoculating cells with the prepared infectious clone.
[0092] The cell refers to a cell transfected with chimeric viral DNA or RNA or a vector, infectious clone or chimeric virus containing the chimeric viral DNA or RNA to produce a large amount of chimeric virus, and the type of the cell is not particularly limited.
[0093] In addition, one example of the present invention may provide a composition for preventing or treating porcine reproductive and respiratory syndrome virus, comprising the vaccine composition.
[0094] As a preferred form, the composition for preventing or treating porcine reproductive and respiratory syndrome virus of the present invention may contain additional components known to those skilled in the art, and may also contain suitable carriers, excipients and diluents commonly used in preparing pharmaceutical compositions.
[0095] In addition, it can also be formulated into oral preparations, external preparations, suppositories and sterile injections such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, etc. It is preferred to use suitable preparations known in the art as disclosed in the document (Remington's Pharmaceutical Science, recently, Mack Publishing Company, Easton PA).
[0096] The carrier, excipient and diluent that can be included in the pharmaceutical composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum arabic, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talcum powder, magnesium stearate and mineral oil. When preparing the composition, diluent or excipient such as filler, extender, adhesive, wetting agent, disintegrant, surfactant etc. are used to prepare. Orally administered solid preparations include tablets, pills, powders, granules, capsules etc., and these solid preparations are prepared by mixing at least one excipient such as starch, calcium carbonate, sucrose, lactose, gelatin etc. into the composition. In addition, in addition to simple excipients, lubricants such as magnesium stearate and talcum powder are also provided. Orally administered liquid preparations include suspensions, oral solutions, emulsions, syrups, etc., and in addition to commonly used simple diluents, water and liquid paraffin, various excipients may also be included, such as wetting agents, sweeteners, air fresheners, preservatives, etc. The preparations administered parenterally include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, and suppositories. As non-aqueous solvents and suspensions, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, esters for injection such as ethyl oleate, etc. may be used. As the base compound of suppositories, witepsol, polyethylene glycol (Macrogol), Tween 61, cocoa butter, lauric acid, glycerin gelatin, etc. may be used.
[0097] The preferred dosage of the composition of the present invention varies according to the subject's condition and body weight, the severity of the disease, the drug form, the route of administration, and the time, and can also be appropriately selected by those skilled in the art. For example, in order to obtain a preferred effect, the composition of the present invention can be administered in an amount of 0.0001 to 1,000 mg / kg (body weight) per day. The composition can be administered once a day or in divided doses.
[0098] The compositions of the present invention can be administered to a subject via a variety of routes. All routes of administration are contemplated.
[0099] Another embodiment of the present invention may provide a method for preventing or treating porcine reproductive and respiratory syndrome, comprising administering the vaccine composition of the present invention to pigs.
[0100] By administering the vaccine composition comprising the chimeric virus genome of the present invention to pigs, the immune response of pigs to PRRSV antigens can be induced and enhanced, and a method for preventing or treating porcine reproductive and respiratory syndrome can be provided by inducing and enhancing the immune response of pigs to PRRSV antigens. Preferably, prevention can be performed.
[0101] Specifically, the method can administer the composition by subcutaneous injection, intravenous injection, intradermal injection, parenteral injection, intramuscular injection, needle-free injection, electroporation, oral delivery, intranasal delivery, oronasal delivery, or any combination thereof.
[0102] The present invention can provide a kit for performing any of the above methods. The kit may include a container, a vaccine composition preferably containing an attenuated PRRS chimeric virus of the present invention, a pharmaceutically acceptable carrier, an adjuvant, and instructions for administering an immunogenic composition to an animal in need to reduce the clinical symptoms or effects of PRRS infection, preferably to reduce the frequency or severity of PRRS. The kit may also include an injection device and / or other types of administration devices. In addition, the kit may include a solvent. The attenuated vaccine can be lyophilized and reconstituted with a solvent to become a solution for injection and / or a solution for inhalation. The solvent can be water, saline, a buffer solution, or an enhanced solvent. The kit may include a separate container containing an attenuated virus, a solvent, and / or a pharmaceutically acceptable carrier. The instructions for use may be a label and / or printed matter attached to one or more containers.
[0103] Beneficial Effects
[0104] The chimeric virus of the PRRSV virus according to the present invention can be used to effectively prevent PRRS by significantly increasing the secretion of neutralizing antibodies when inoculated into pigs, and can be effectively used as a vaccine for treating PRRS. BRIEF DESCRIPTION OF THE DRAWINGS
[0105] Figure 1 The general genomic arrangement of PRRS virus is shown.
[0106] Figure 2 Schematic diagram of the genome arrangement of the LMY+BP2017 chimeric virus synthesized by cutting out parts of the clones of the LMY ver2 virus and the BP2017-2 virus, respectively, and ligating them.
[0107] Figure 3 The phylogenetic tree of PRRSV LMY ver2 virus and LMY+BP2017 chimeric virus is shown.
[0108] Figure 4 The differences in the proliferation characteristics of PRRSV LMY ver2 virus and LMY+BP2017 chimeric virus in porcine alveolar macrophages (PAM cells) are shown.
[0109] Figure 5 The differences in the secretion of neutralizing antibodies after pigs were inoculated with PRRSV LMY, LMY+BP2017 chimeric virus and PBS were compared. DETAILED DESCRIPTION
[0110] Hereinafter, the present invention will be described in detail by way of examples. However, the following examples are only used to illustrate the present invention, and the present invention is not limited by the following examples.
[0111] Since RNA is easily destroyed, cells are transfected by synthesizing RNA from it after converting it to DNA to do all the work.
[0112] Example 1: Preparation of chimeric viruses
[0113] 1-1. Design of chimeric virus
[0114] The PRRS chimeric virus was designed to contain the non-structural protein (Non structure Protein 1, NSP1; SEQ ID NO: 11) region of the mutant strain of the LMY strain and the ORF2, ORF3, ORF4, ORF5, ORF6 and ORF7 regions of BP2017-2 isolated in 2017.
[0115] 1-2. Preparation of attenuated LMY mutant strain
[0116] The LMY ver2 mutant strain was prepared by replacing 91 bases of the nucleotide sequence of the NSP1 region gene with the LMY strain (GenBank Accession No. DQ473474.1.), which is a PRRS strain isolated by the Quarantine Agency. In the NSP1 region gene, 25 bases of the NSP1-α region and 66 bases of the NSP1-β region were replaced.
[0117] Specifically, recombinant strain LMY ver2 is to use well-known SAVE (synthetic attenuated virus engineering) program or SAVE (synthetic attenuated virus engineering) program developed by the inventor, according to the codon pair deoptimization principle (Table 3), by a part of nucleotide sequence being carried out silent mutation to prepare.First, use SAVE program to quantify CPB (codon pair base) score with computer algorithm, CPB score is the deviation caused by interaction when the gene codon of LMY virus is arranged in pairs. CPB score fluctuates when some nucleotide sequences of LMY virus gene are replaced by other nucleotide sequences, and is closely related to the proliferation characteristics of virus. When CPB score is deoptimized by nucleotide sequence replacement, virus proliferation characteristics can be reduced and weakened (virus attenuation caused by genome scale change of codon pair preference (Virus Attenuation by Genome-ScaleChanges in Codon Pair Bias, Science), Science, 2008, J.Robert Coleman et al.). The present inventors selected NSP1 regions (NSP1-α and NSP1-β, SEQ ID NO: 11) with high genetic stability in the genome of the LMY parent strain and analyzed them using the SAVE program, and selected 25 bases in the NSP1-α region and 66 bases in the NSP1-β region (a total of 91 bases) from the base regions with relatively high CPB scores and replaced them with other bases, thereby preparing LMY virus mutants. The LMY virus mutant strain in which the sequence of 91 nucleotides of NSP1 is mutated (SEQ ID NO: 12) prepared by this method is named LMY ver2, and its nucleotide sequence is shown in Table 3 below. The deposit number of LMY ver2 is KCTC 13394BP.
[0118] [Table 3]
[0119]
[0120]
[0121]
[0122] (In Table 3, the bold and underlined parts in the LMY ver2 NSP1 gene sequence are the base parts where mutations occur in the LMY NSP1 gene or the LMY NSP1-β gene.)
[0123] Then, in order to confirm the degree of attenuation of the LMY ver2 mutant, the CPB score was measured. The NSP1 CPB score of the LMY parent strain was measured to be about 0.0139, and the NSP1-β CPB score was measured to be about 0.016, but the CPB score of the LMY ver2 mutant of the present invention was measured to be about -0.2393 in NSP1 and about -0.33 in NSP1-β. It can be seen that the LMYver2 mutant of the present invention has a reduced proliferation characteristic compared with the conventional parent strain and is an attenuated strain.
[0124] [Table 4]
[0125]
[0126]
[0127] Then, infectious clones of LMY ver2 were prepared.
[0128] First, the whole gene sequence of the LMY strain (GenBank accession number DQ473474.1.) was divided into 7 fragments and synthesized separately. Among the 7 fragments, fragment 1 was the NPS-1 region, and this region was synthesized as a DNA fragment (SEQ ID NO: 12) in which 91 bases in the gene nucleotide sequence of the NSP1 region of the LMY strain were replaced. The synthesized fragment genes were sequentially cut with the restriction enzymes shown in Table 5 below and ligated with ligase to prepare an infectious clone.
[0129] [Table 5]
[0130]
[0131] 1-3. Construction of chimeric virus clones
[0132] like Figure 1 As shown in the schematic diagram, PRRS virus contains a total of 8 ORFS, namely ORF1a, ORF1b, ORF2 to 7.
[0133] In the genomic region containing the complete structural gene of the LMY ver2 mutant amplified in Example 1-1, the ORF2 to ORF7 region was cut using restriction enzymes AscI and PacI. Subsequently, the portion of the genomic region of the BP2017 strain corresponding to the ORF2 to ORF7 region of the LMY ver2 mutant was cut using the same restriction enzymes AscI and PacI, and then the ORF1a and ORF1b portions of the LMY ver2 mutant and the portion corresponding to the ORF2 to ORF7 region of the BP2017 strain were ligated with ligase to prepare a recombinant infectious clone, named LMY+BP2017. The restriction enzymes used are shown in Table 6 below.
[0134] [Table 6]
[0135]
[0136] The completed infectious clone was inserted into a high-copy vector loaded with a CMV promoter and an ampicillin resistance gene, and then transfected into BHK cells (Korean cell line bank) using liposomes, and finally the LMY+BP2017 chimeric virus of the present invention was constructed.
[0137] The LMY+BP2017 chimeric virus was deposited at the Microbial Resource Center of the Korea Institute of Biotechnology on October 24, 2018, and was given the deposit number KCTC 13675BP.
[0138] Example 2. Measurement of CpG and UpA values of LMY+BP2017 chimeric virus
[0139] In order to evaluate the proliferation characteristics of the LMY+BP2017 chimeric virus prepared in Example 1, the ratio of CpG to UpA in the NSP1 gene of the LMY+BP2017 chimeric virus and the CpG and UpA values in the NSP1β gene of the parent strain LMY were measured.
[0140] The change in the ratio of CpG and UpA of viral genes is an inevitable result of the deoptimization process. When the CpG and UpA values of genes increase, cell stress is induced and the viral proliferation characteristics are reduced. The CpG and UpA ratios in the NSP1β gene of LMY+BP2017 chimeric virus and LMY virus were measured using the SSE program (version 1.2), and the results are shown in Table 7 below.
[0141] [Table 7]
[0142] Classification CpG Ua LMY 0.6394 0.7066 LMY+BP2017 chimera 1.1753 1.03
[0143] As shown in Table 7, it was confirmed that the CpG and UpA values of the LMY+BP2017 chimeric virus were increased compared with the parent strain LMY, thereby confirming that the proliferation characteristics of the LMY+BP2017 chimeric virus were significantly reduced compared with the LMY parent strain.
[0144] Example 3. Identification of LMY+BP2017 chimeric strains
[0145] 3-1. Identification of LMY+BP2017 chimera strain
[0146] The NSP1 region of the LMY+BP2017 chimeric strain synthesized in Example 1 and the LMY strain (GenBank Accession No. DQ473474.1.) was sequenced to identify the LMY+BP2017 chimeric strain.
[0147] Specifically, PCR was performed using the primer set of 1 to 1654 nt capable of detecting the NSP1 region including LMY virus in Table 8 and a one-step RT PCR kit (Intron), specifically, after the initial RT process was performed at 45°C for 30 minutes and at 95°C for 5 minutes, 94°C for 30 seconds, 61°C for 30 seconds and 72°C for 2 minutes, and this process was repeated 38 times. Then, the amplified product as a result of the PCR was sequenced to complete the identification of each strain.
[0148] [Table 8]
[0149] Primers Nucleotide sequence (5'→3') SEQ ID NO Forward primer ATGACGTATAGGTGTTGGCTCTA 9 Reverse primer CTGAGGATTTGGATGGCATT 10
[0150] 3-2. Homology comparison with other strains and phylogenetic tree
[0151] To confirm the genetic differences between the recombinant virus strain LMY ver2 of the present invention prepared in Example 1 and known PRRS virus strains, the NSP1 region sequence homology of each strain was measured using the bioedit program. Table 9 shows the homology comparison results.
[0152] [Table 9]
[0153]
[0154] As shown in Table 9, the results of homology comparison show that the LMY+BP chimeric virus has a unique sequence different from other PRRS strains.
[0155] According to the results of homology comparison, the phylogenetic tree was analyzed using the bioedit program and Bootstrap was repeated 1000 times. On this basis, a rough phylogenetic tree of LMY+BP2017 chimeric virus and LMY was compiled, as shown in Figure 3 As shown. Figure 3 The phylogenetic tree can help us understand the system of this virus.
[0156] 3-3. Cell passage studies
[0157] It was confirmed how long the modified region can be maintained during the passage of the LMY+BP2017 chimeric virus produced in Example 1. The LMY+BP2017 chimeric virus of the present invention was stable over 30 passages in MARC-145 cells, which is known as a PRRS virus soluble cell line, and sequencing was performed using the same method as in Example 3-1 to confirm the gene mutation every 10 passages.
[0158] The results of sequencing confirmation confirmed that the gene replacement region of the present virus can be maintained even after 30 stable passages. In Table 10 below, the number of base mutations (nt changes), mutation sites and amino acid mutations (aa changes) according to each passage number are shown.
[0159] [Table 10]
[0160]
[0161] As can be confirmed in Table 10, even after passage for more than 30 times, the mutation in the NSP1a or NSP1b gene of ORF1a remained intact, and only the mutation in the NSP2 protein or ORF2a was identified. Therefore, it was confirmed that the mutation in the gene encoding the NSP1 protein of the virus produced in Example 1 remained even after passage for 40 times.
[0162] Example 4: Comparison of proliferation characteristics of LMY and LMY+BP chimeras
[0163] In order to confirm the proliferation characteristics of the LMY+BP2017 chimeric virus prepared in Example 1, the LMY+BP2017 chimeric virus and its parent strain were inoculated into macrophages (PAM, porcine alveolar macrophages) and the TCID 50 Determine the amount of virus produced.
[0164] Specifically, PAM cells were plated at 2 × 10 per well. 6 The cells / well were aliquoted into 6-well plates containing 2 ml RPMI medium (containing 10% FBS, 1% penicillin and streptomycin). Then LMY and LMY+BP2017 chimeric viruses were inoculated into different wells at an MOI of 0.01. All supernatants were removed 1 hour after inoculation and aliquoted into 2 ml maintenance RPMI medium (containing 10% FBS, 1% penicillin and streptomycin). Two days after aliquoting, the supernatant of each well was collected and the TCID 50 (Tissue Culture Infectious Dose 50 ). For cells used in subsequent experiments, TCID 50 The day before, 100ul DMEM medium (10% (v / v) FBS, 1% (w / v) penicillin, streptomycin) was mixed with 2X10 5 MARC-145 cells were aliquoted into a 96-well plate at 10 cells / well and the cells were allowed to adhere.
[0165] Prepare the virus to be inoculated as follows. Divide 200 μL of the previously collected supernatant into the leftmost column of wells on the 96-well plate, and divide 180 μL of DMEM culture medium (FBS, without antibiotics) into each of the remaining wells. Next, use a multichannel pipette to take 20 μL each from the left side, and dilute 10 times when dividing into the wells on the right. Dilute in sequence while changing the tip of the gun, and leave the last 12 wells as negative controls. Inoculate the prepared virus dilution into a plate with MARC-145 cells attached. Then, remove all the culture medium of MARC-145 cells, divide 200 μL of PBS into each well, and discard it repeatedly 3 times for the washing process. Afterwards, divide 100uL of the prepared virus dilution into each well for inoculation, remove all the inoculation solution within 2 hours after inoculation, and divide 100 μL of new maintenance solution (DMEM culture medium, 10% FBS, 1% penicillin, streptomycin).
[0166] About 7 days after aliquoting, the occurrence of aggregation and apoptosis as a type of CPE (cytopathogenic effect) in the cells was confirmed, and finally the dilution of the 4 wells (half of the 8 virus inocula) that showed CPE was calculated based on the dilution of the wells that did not show CPE previously. The final value was calculated by multiplying by 10 based on 1 ml.
[0167] The LMY+BP2017 chimeric strain and the parental LMY strain were inoculated into porcine alveolar macrophages (PAM cells), and the TCID 50 The values are shown in Table 11 and Figure 4 .
[0168] [Table 11]
[0169]
[0170] As shown in Table 11 and Figure 4 As shown, TCID was measured on the second day after inoculation of the strain and the start of formal virus production. 50 The values show that the TCID 50 The value is the TCID of LMY 50 It can be seen from this that the proliferation characteristics of the LMY+BP2017 chimeric virus of the present invention in PAM (porcine alveolar macrophages) cells, which are the main infected cells of PRRS, are reduced to at least 1 / 10 compared with LMY, and it can be confirmed that the LMY+BP2017 chimeric virus of the present invention is attenuated because its proliferation characteristics are lower than those of the parent strain LMY.
[0171] Example 4: Confirmation of neutralizing antibody secretion pattern
[0172] After inoculation with the chimeric virus of the present invention, in order to confirm the secretion pattern of neutralizing antibodies, 12 3-week-old pigs were divided into 3 groups, each with 4 pigs, and inoculated with 2 ml of LMY (10 5 TCID 50 ), LMY+BP2017 chimeric virus (10 5 TCID 50 ) and PBS. After 4 weeks, blood was collected from the vein of each group of pigs, 2 ml of serum was separated, and the amount of neutralizing antibodies in the serum was determined.
[0173] Specifically, the test method is carried out according to conventional well-known methods. All serum samples were heat-inactivated at 56°C for 45 minutes before starting the test. The inactivated serum was added to RPMI 1640 medium (10% FCS, 20mM L-glutamine, antibiotic-antimycotic mixture-100IU / ml penicillin, 100μg / ml streptomycin, 50μg / ml gentamicin, 0.25mg / ml amphotericin B) and diluted twice. Subsequently, 100μl of the diluted serum was collected and mixed with 100μl of 200TCID prepared in advance. 50 / ml of VR2332 strain was mixed, incubated at 37°C for 1 hour, and then inoculated with Marc-145 cells in a monolayer state that had been cultured in advance the day before. Subsequently, all the inoculation solutions after culturing at 37°C for 1 hour were removed in sequence and replaced with 200μl of RPMI culture medium. Thereafter, the cytopathic effect (CPE) was checked while culturing at 37°C every day, and the CPE of each well was confirmed after 5 days of culture. In the wells without CPE, the growth of the virus was confirmed by staining with SDOW 17 antibody. The titer of the neutralizing antibody was measured by calculating the reciprocal of the highest dilution factor with no sign of viral growth, and the measurement results are shown in the following Tables 12 and Figure 5 middle.
[0174] [Table 12]
[0175] Inoculation strain LMY LMY+BP2017 chimera PBS (control) <![CDATA[Neutralizing antibody (Log2)]]> 2.75 4.75 0
[0176] As shown in Table 12 and Figure 5 As shown, it can be confirmed that the LMY+BP2017 chimeric virus secreted significantly higher neutralizing antibodies in cells compared with the LMY parental strain.
[0177] (Chinese translation)
[0178] Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure
[0179] Recipient: BIOPOA Co., Ltd.
[0180] 105-11, Sinjeong-ro, Giheung-gu, Yongin-si, Gyeonggi-do 17093
[0181]
[0182] The above translation does not contradict the original text.
[0183] (Chinese translation)
[0184] Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure
[0185] Recipient: BIOPOA Co., Ltd.
[0186] 105-11, Sinjeong-ro, Giheung-gu, Yongin-si, Gyeonggi-do 17093
[0187]
[0188] The above translation does not contradict the original text.
[0189] (Chinese translation)
[0190] Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure
[0191] Recipient: BIOPOA Co., Ltd.
[0192] 105-11, Sinjeong-ro, Giheung-gu, Yongin-si, Gyeonggi-do 17093
[0193]
[0194] The above translation does not contradict the original text.
Claims
1. A polynucleotide consisting of the structure of structural formula 1, wherein the polynucleotide is the genome of a chimeric virus of porcine reproductive and respiratory syndrome virus (PRRSV): [Structural Formula 1] 5'-[X]-[Y]-3' in, [X] is the nucleic acid sequence of the genes in the ORF1a and ORF1b regions of the NSP1 gene of the LMY ver2 mutant strain with a deposit number of KCTC 13394BP, and [Y] is the nucleic acid sequence of the ORF2 to ORF7 region of the BP2017-2 mutant strain with a deposit number of KCTC 13393BP, Wherein, the structural formula 1 is represented by the nucleic acid sequence of SEQ ID NO:
4.
2. A PRRSV chimeric virus comprising the polynucleotide of claim 1 as a genome.
3. The virus according to claim 2, in, The deposit number of the chimeric virus is KCTC 13675BP.
4. A porcine reproductive and respiratory syndrome virus vaccine composition comprising the PRRSV chimeric virus or its subcultured progeny according to claim 2.
5. The vaccine composition according to claim 4, in, The deposit number of the chimeric virus is KCTC13675BP.
6. The vaccine composition according to claim 4, in, The vaccine is a live vaccine.
7. The vaccine composition according to claim 4, in, The vaccine further comprises one or more selected from the group consisting of a carrier, a diluent, an excipient and an adjuvant.
8. The vaccine composition according to claim 4, in, After the vaccine composition and the parent strain of the chimeric virus with accession number DQ473474.1 were inoculated into porcine lung macrophages, the TCID 50 The value is the TCID of the parent strain 50 0.01 to 0.1 times the value.
9. The vaccine composition according to claim 4, in, After the vaccine composition and the parent strain of the chimeric virus with accession number DQ473474.1 were inoculated into pig lung macrophages, the neutralizing antibody value of the chimeric virus was measured to be 2 to 8 times that of the parent strain.
10. A method for producing a chimeric virus of porcine reproductive and respiratory syndrome virus (PRRSV), include: The genome of the LMY ver2 mutant strain with a deposit number of KCTC 13394BP was treated with restriction enzymes AscI and PacI to prepare polynucleotide fragments; Treating the genome of the BP2017-2 mutant strain with a deposit number of KCTC 13393BP with restriction enzymes AscI and PacI to prepare polynucleotide fragments; and Recombining the polynucleotide fragment of LMY ver2 and the polynucleotide fragment of BP2017-2 to prepare an infectious clone, The recombinant polynucleotide fragment consists of the nucleic acid sequence of SEQ ID NO:
4.
11. The method for producing a chimeric virus according to claim 10, in, The polynucleotide fragment prepared by treating the genome of the LMY ver2 mutant strain with restriction enzymes AscI and PacI contains a region encoding the NSP1 protein.
12. The method for producing a chimeric virus according to claim 10, in, The polynucleotide fragment prepared by treating the genome of the BP2017-2 mutant strain with restriction enzymes AscI and PacI includes the ORF2 to ORF7 regions.
13. A pharmaceutical composition for preventing or treating porcine reproductive and respiratory syndrome, comprising the vaccine composition according to claim 4.
14. Use of the vaccine composition according to claim 4 in the preparation of a medicament for preventing or treating porcine reproductive and respiratory syndrome.
